Dr. Katherine Harris is Vice President of Discovery, joining Teneobio in 2015. Her team employs a sequence-based approach for antibody discovery that leverages next-generation sequencing and high throughput functional assays to develop fully-human multi-specific antibodies. Prior to her work at Teneobio, she led development of a functional genomics platform for small molecule screening at Active Motif and SwitchGear Genomics. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She has presented at numerous national and international forums and has multiple peer-reviewed publications and issued patents.